This study highlights the potential of Rapaxane,a ratiometricdrug delivery system consisting of PEG-b-PLA micellescoloaded with oligo­(lactic acid)8 conjugated prodrugs ofpaclitaxel (oLA8-PTX) and rapamycin (oLA8-RAP),for treating triple-negative breast cancer. The gene discussed is LRPAP1; the disease is triple-negative breast carcinoma.